Member Info for Safy

There was some confusion about our closing price yesterday. It wasnt as high as we thought based on the opening price.

Presently we are around 8.5% down, not saying this is good. But its not the nearly double figure posted on this site. Less panic.

may NOT be what you wanted to read BUT look at all the positives.

The Company announces it has signed a Supply Agreement with Mologic Ltd ("Mologic") under which Mologic will supply raw materials to enable Omega to manufacture its CE-Marked ELISA1 antibody test. The antibody test will play a key part in identifying people that have antibodies demonstrating previous infection with COVID-19. The Agreement is for an initial period of three years and renewable annually thereafter.

I've posted before, one of the hardest parts of testing is getting the raw materials to do the tests. The WHOLE world wants them. Not just ODX or any other bio pharma. The whole world wants to ramp up tests, and this Covid-19 pandemic is spreading by the day. Its higher now than its ever been. They have an agreement for 3 years to get materials. That means that ODX expect this testing trend to continue for at least 3 years.

In addition, Omega announces it has widened its collaboration with Mologic by signing another Material Transfer Agreement ("MTA"), providing the Company with access to raw materials and know-how to manufacture the following additional Mologic COVID-19 tests:



· an ELISA antigen test that determines the concentration of COVID-19 (SARS-CoV-2) antigens in human blood, saliva or swab extract sample thereby identifying an individual with an active COVID-19 infection

· a lateral flow antigen test product that determines the concentration of COVID-19 (SARS-CoV-2) antigens in a human blood, saliva, or swab extract sample also used to identify an individual with an infection

· a lateral flow antibody test product that determines the concentration of human antibodies in a human blood sample specifically targeting the COVID-19 (SARS-CoV-2) antigens

'providing the Company with access to raw materials and know-how to manufacture the following additional Mologic COVID-19 tests:'

That is the key statement, their products to market will increase, their technological capabilities will increase, how the heck is that a bad thing? more products to market means more earnings for ODX.

Granted the 100k sales to Senegal was a damp squib, but more importantly they have secured materials for 3 years in a contract, and got more tests in the pipeline.

US green and no sign of a major hiccup all effin day.

@Alwaysone

Can you give a brief overview of what you know? And what’s expected pls?

@AlwaysOne

What do you know about SKIN that we dont know :-)

its almost like i wipe the optimism away and this share starts going north....

strangely its creeping up before close, whereas the trend is reverse at close, and a small bump after market.
US is blue.

and dropped again

WTF!! straight after auction

Agree axe, this isn’t a 10 year wait for 500p

Just go off the broker analysis, they know what they are talking about.

Ready to hit the sack

Let’s wait till tomorrow. For the record this sort of thing (reselling) commission type of work, is massive in India. Just go on alibaba and view how many middle men in India pretend to be business owners.

Oddly the poster who put up the link only has 3 posts. All GDR.... mmm

Look forward to tomorrow. Night

Magsy, think he could be a small partner trying to push out some testing in the private sector and gauging the market.

But the plus side is, someone with entrepreneurial skills sees the GDR test as a viable option for India.

https://twitter.com/nhsccio/status/1253946486615937024?s=21

And he has a vested interest in the UK testing scene.

This is his Twitter

https://twitter.com/kanavkahol

http://www.pinktechdesign.com/

That’s him on the page. The Indian partner. He already has some funding from Indian gov on a covid device according to one of his tweets.

https://www.divoc.health/news

Updated on Saturday

Dr kanav kahol checks out. He’s on the covid scene.

Website looks a bit **** but if it’s legit then an RNS has to come tomorrow as this a partner for GDR.

Says StemprintER

Top man Axe

Can you please post the URL for this write up?

Apologies not sure why I used the 10+ year example.

Feel free to read the above, most PI’s will be able to conclude whether the company timeframes match their ambitions.

Failing that I would stick to the broker targets of £5 for the year.

Rorkes - Same here. Good luck with that.

Tils’ plays are not a 10 year investment plan. Ofc anyone can keep shares as long as they wish. But the pipeline isn’t a 10 years wait. A bit of research on their website will tell you this.

Around 70% of potential new drugs pass Phase 1 and enter Phase 2, which continues to measure safety, while looking at how effective the treatment is, too. Phase 2 trials recruit up to several hundred patients with the condition to take part. This phase typically lasts several months to two years

Just 33% of drugs make it past Phase 2 and into Phase 3, which tests the potential treatment in the largest number of people. This phase measures both safety and effectiveness with many volunteers, sometimes thousands. Phase 3 trials last from one to three years.

After Phase 3, a pharmaceutical company may submit a New Drug Application (NDA) for the treatment to the Food and Drug Administration (FDA). The FDA then reviews results from all stages of the trial to determine whether it will approve the drug and allow the pharmaceutical company to begin marketing it to the public.

https://www.tizianalifesciences.com/our-drugs/

The link above shows the phases these drugs are at. Though for the latest update on miciclib refer to the RNS as the website needs updating.

Hope this helps.

I